CP
TVTX icon

CenterBook Partners’s Travere Therapeutics TVTX Stock Holding History

CenterBook Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.67M Buy
+157,122
New +$4.7M 0.25% 107

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CenterBook Partners's TVTX Position: Q1 2026 in Review

CenterBook Partners opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 157,122 shares worth $4.67M. The stake represents 0.25% of the portfolio and ranks #107 among its holdings.

260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • CenterBook Partners held 157,122 shares of Travere Therapeutics worth $4.67M as of Q1 2026.
  • Travere Therapeutics was a new CenterBook Partners position in Q1 2026.
  • Travere Therapeutics made up 0.25% of CenterBook Partners's portfolio in Q1 2026, its #107 holding.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.